GC Biopharma Corp. (KRX:006280)

Market Cap	1.51T
Revenue (ttm)	1.79T
Net Income (ttm)	73.65B
Shares Out	11.41M
EPS (ttm)	6,453.27
PE Ratio	20.45
Forward PE	25.61
Dividend	1,500.00 (1.14%)
Ex-Dividend Date	Dec 27, 2024

Volume	47,578
Average Volume	33,716
Open	130,200
Previous Close	129,300
Day's Range	129,200 - 132,500
52-Week Range	111,800 - 181,800
Beta	1.05
RSI	46.51
Earnings Date	Nov 14, 2025

About GC Biopharma

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for heredit...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1967
• Employees: 2,042
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 006280

Financial Performance

In 2024, GC Biopharma's revenue was 1.68 trillion, an increase of 3.27% compared to the previous year's 1.63 trillion. Losses were -26.28 billion, -1.32% less than in 2023.